蚂蚁淘生物做为Avidity的一级代理商,竭诚为您服务!
【订购】蚂蚁淘生物科技 联系方式:4000-520-616
更多产品,更多优惠!请联系我们!
苏州蚂蚁淘生物科技有限公司
咨询热线:4000-520-616
蚂蚁淘官网:https://www.ebiomall.cn/
Avidity研发和销售用于分子连接的分子亲和工具,其的AviTag™技术采用针对性很强的一个独特的15氨基酸肽,用来自大肠杆菌的生物素连接酶(BirA)标签上的单一的生物素酶的共轭。
部分产品目录:
|
货号 |
品名 |
规格 |
品牌 |
|---|---|---|---|
|
AVB100 |
AVB100 - Glycerol Stock |
0.5ml |
Avidity |
|
EVB100 |
EVB100 electro-competent cells |
10x50μl |
Avidity |
|
AVB99 |
AVB99 - Glycerol Stock |
0.5ml |
Avidity |
|
BIP300 |
BIP-300 - positive control plasmid for induction |
2μg |
Avidity |
|
BirA500 |
BirA-500: BirA biotin-protein ligase standard reaction kit |
ea |
Avidity |
|
Bulk BirA |
Bulk BirA: BirA biotin-protein ligase bulk reaction kit |
ea |
Avidity |
|
BIS300 |
BIS-300 positive and negative control protein kit |
ea |
Avidity |
亲和生物科学公司是一家私营生物技术公司,是一家开创抗体寡核苷酸结合(AOC)的公司。™)AOCs结合了单克隆抗体的组织选择性和基于寡核苷酸的治疗方法的精确性,以克服寡核苷酸传递的障碍和疾病的目标遗传驱动因素。它们的AOC平台,演示了疾病相关RNA在细胞类型和组织中的调节,包括肌肉、心脏、肝脏、肿瘤和免疫细胞。专有的平台技术可以在单一抗体支架上传递多种治疗性寡核苷酸。AOCs具有类似于抗体的药物性质,并允许将寡核苷酸有效载荷传递到其他运载平台所不提供的非肝组织。AOC也有其独特之处,因为可以处理不可药物的目标。
它们正在推进一系列的治疗计划,重点是罕见的肌肉疾病和其他严重疾病。主要项目是开发治疗杜氏肌营养不良和肌营养不良患者的治疗方法。还与制药合作伙伴合作开展项目。并得到了经验丰富的团队和受人尊敬的生命科学投资者的支持。

Avidity带有AviTag标签的人类全长ORF克隆已经被构建在多种T7和CMV启动子表达系统,可以立即购买使用。AviTag标签蛋白可以被体内或体外的生物素连接酶生物素化,而且抗生物素蛋白或链霉亲和素可以专一地与生物素结合,正基于这两个反应,AviTag?技术可以应用于蛋白的固定,纯化和显影。 虽然Avidity是一个小公司,科学带来的好处及其AviTag已得到认可。目前, AviTag技术已经在22个国家的世界十大制药公司和研究人员中得到认可。
Avidity develops and sells molecular affinity tools for connecting molecules. Our patented AviTag™ technology employs a highly targeted enzymatic conjugation of a single biotin on a unique 15 amino acid peptide tag using the biotin ligase (BirA) from E. coli. AviTag™ sequence is GLNDIFEAQKIEWHE. Oriented on streptavidin-coated surfaces, this creates an ideal presentation for molecular binding interactions.
The scientific benefits of Avidity's AviTag Technology have garnered notice. Currently, AviTag technology is licensed by seven of the world's top ten pharmaceutical companies and is used by researchers in 22 countries.
Avidity, LLC was founded in 1996 by Millard Cull, Larry Lansing, Dr. Ron Gill, and Dr. Mark Seville to develop peptide tags and molecular biology products based upon the extraordinary affinity of biotin for avidin or streptavidin. While working at Affymax as a researcher, Millard was involved in the discovery of the AviTag technology, saw its commercial potential, and obtained the exclusive rights from Affymax. He started Avidity as a reagent company that sublicenses the right to use the AviTag technology to other companies and sells products for use with the technology.
AviTag is a patented biotin-tagging technology discovered at Affymax by Dr. Peter Schatz from a Directed Evolution approach called "Peptides-on-Plasmids." The Directed Evolution approach identified a number of peptide sequences that can be biotinylated by the BirA enzyme of E. coli, and the best of these sequences was called the AviTag. E. coli enzyme BirA biotinylates the 15 amino acid AviTag twice as fast as its natural substrate, the Biotin Carboxyl Carrier Protein (BCCP).
The enzymatic biotinylation of proteins using AviTag technology is preferred over chemical biotinylation of proteins because BirA enzyme gently, and highly specifically, labels the lysine residue of the AviTag. Prior to the AviTag, the smallest biotin-accepting domain was comprised of 75 amino acids.